E3 ubiquitin ligase SYVN1 as a promising therapeutic target for diverse human diseases
- PMID: 39818260
- DOI: 10.1016/j.phrs.2025.107603
E3 ubiquitin ligase SYVN1 as a promising therapeutic target for diverse human diseases
Abstract
Numerous studies conducted in recent years indicate that mammalian E3 ubiquitin ligases serve as key regulators in the maintenance of cellular homeostasis by targeting the ubiquitination of substrate proteins and activating downstream signaling pathways. SYVN1, an E3 ubiquitin ligase, is characterized by its significant functions in regulating various biological processes, including molecular mechanisms related to gene expression, signaling pathways, and cell death, among others. Consequently, SYVN1 plays a crucial role in both normal human physiology and the pathogenesis of various diseases, such as oncogenesis, cardiovascular disorders, immune regulation, skeletal anomalies, and neurological diseases. This review synthesizes recent findings regarding the physiological and pathophysiological roles of SYVN1, offering new insights into potential strategies for the prevention and treatment of human diseases, as well as suggesting avenues for future drug development. In this Review, we summarize the latest findings regarding the physiological and pathophysiological roles of SYVN1, elucidating the mechanisms by which SYVN1 can regulate the progression of various diseases in humans. These important findings provide new avenues for further investigation of SYVN1 protein, new insights into potential strategies to prevent and treat human diseases, and new directions for future drug development.
Keywords: Cancer disease; E3 ubiquitin ligase; SYVN1.
Copyright © 2025 The Authors. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare that there are no conflicts of interests.
Similar articles
-
Integrative proteomics reveals the role of E3 ubiquitin ligase SYVN1 in hepatocellular carcinoma metastasis.Cancer Commun (Lond). 2021 Oct;41(10):1007-1023. doi: 10.1002/cac2.12192. Epub 2021 Jul 1. Cancer Commun (Lond). 2021. PMID: 34196494 Free PMC article.
-
E3 ubiquitin ligase WWP2 as a promising therapeutic target for diverse human diseases.Mol Aspects Med. 2024 Apr;96:101257. doi: 10.1016/j.mam.2024.101257. Epub 2024 Mar 2. Mol Aspects Med. 2024. PMID: 38430667 Review.
-
Novel Insights Into E3 Ubiquitin Ligase in Cancer Chemoresistance.Am J Med Sci. 2018 Apr;355(4):368-376. doi: 10.1016/j.amjms.2017.12.012. Epub 2017 Dec 28. Am J Med Sci. 2018. PMID: 29661351 Review.
-
E3 ubiquitin ligase SYVN1 is a key positive regulator for GSDMD-mediated pyroptosis.Cell Death Dis. 2022 Feb 3;13(2):106. doi: 10.1038/s41419-022-04553-x. Cell Death Dis. 2022. PMID: 35115505 Free PMC article.
-
Mammalian HECT ubiquitin-protein ligases: biological and pathophysiological aspects.Biochim Biophys Acta. 2014 Jan;1843(1):61-74. doi: 10.1016/j.bbamcr.2013.03.024. Epub 2013 Mar 29. Biochim Biophys Acta. 2014. PMID: 23545411 Review.
Cited by
-
NRF2 activation in cancer and overview of NRF2 small molecule inhibitors.Arch Pharm Res. 2025 Aug 15. doi: 10.1007/s12272-025-01557-x. Online ahead of print. Arch Pharm Res. 2025. PMID: 40815486 Review.
-
Dihydrotanshinone I Targets PGAM1 to Induce SYVN1-Mediated Ubiquitination and Suppress Glycolysis in Hepatocellular Carcinoma.Phytother Res. 2025 Aug;39(8):3762-3783. doi: 10.1002/ptr.70017. Epub 2025 Jul 10. Phytother Res. 2025. PMID: 40640077 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources